Mometasone - EsoCap
Alternative Names: ESO 101; Mometasone furoate - EsoCapLatest Information Update: 23 Dec 2024
At a glance
- Originator EsoCap AG
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Eosinophilic oesophagitis
Most Recent Events
- 17 Dec 2024 Efficacy and adverse event data from the phase II ACESO trial in Eosinophilic oesophagitis released by EsoCap AG
- 12 Oct 2024 Efficacy data from a phase II ACESO trial in Eosinophilic-oesophagitis presented at the 32nd United European Gastroenterology Week (UEGW-2024)
- 05 Dec 2023 Efficacy and adverse event data from the phase II ACESO trial in Eosinophilic oesophagitis released by EsoCap AG